Spring Bank Pharmaceuticals Inc
Spring Bank Pharmaceuticals — Investor Presentation (November 2018)
31 slides from Spring Bank Pharmaceuticals's investor presentation, Nov 6, 2018
Slide 1: Driven by a novel pharmaceutical platform focused on selective immunomodulation
Driven by a novel pharmaceutical platform focused on SELECTIVE IMMUNOMODULATION Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements, other than historical facts, regarding: the progress, scope, duration or re
Slide 3: Spring Bank Investment Opportunity
1 • SPRING BANK PHARMACEUTICALS, INC. © 2018 Novel, proprietary platform of selective small molecule immunomodulators Rapid generation of product candidates, shortening development time Application across multiple therapeutic areas including viral infections, inflammation and oncology Potent antivir
Slide 4: Differentiated Platform & Near Term Catalysts for Potential Valuation Acceleration
2 • SPRING BANK PHARMACEUTICALS, INC. © 2018 DIFFERENTIATED PLATFORM & NEAR TERM CATALYSTS FOR POTENTIAL VALUATION ACCELERATION Small Molecule Nucleotide Hybrid Platform NEAR–TERM DEVELOPMENT CATALYSTS Platform focused on immunomodulatory targets based on endogenous nucleotide ligands Rapid evolutio
Slide 5: Differentiated Platform & Near Term Catalysts: Near-Term Development Catalysts
Inarigivir, selective RIG-I agonist, in Ph II development for HBV with planned initiation of Ph IIb / III in early 2019 Clinical collaboration with Gilead Differentiated, next-generation STING agonist program in Immuno-oncology SB 11285 will potentially be first IV STING agonist to enter the clinic
Slide 6: Progressive Pipeline Designed to Meet Significant Unmet Needs
4 • SPRING BANK PHARMACEUTICALS, INC. © 2018 PROGRESSIVE PIPELINE DESIGNED TO MEET SIGNIFICANT UNMET NEEDS Platform Targets RIG-I STING Agonists Compound Inarigivir (oral): Monotherapy Co-Administration with Gilead’s Vemlidy® Co-Administration with NUCs SB 9225 inarigivir + tenofovir disoproxil fuma
Slide 7: Chronic HBV: A Global Problem
5 • SPRING BANK PHARMACEUTICALS, INC. © 2018 CHRONIC HBV: A GLOBAL PROBLEM Chronic HBV infection prevalence (approximate) ~257MM GLOBALLY ~17MM US AND EUROPE Estimated Deaths ~900,000 (IN 2017) HBV NUC global therapeutics sales $2.1B (IN 2017) LOW TREATMENT RATES OF CHRONIC HBV PATIENTS Estimated 10
Slide 8: An Opportunity to Change the Chronic HBV Paradigm by Elevating the Functional Cure Rate
6 • SPRING BANK PHARMACEUTICALS, INC. © 2018 AN OPPORTUNITY TO CHANGE THE CHRONIC HBV PARADIGM BY ELEVATING THE FUNCTIONAL CURE RATE A meaningful new therapy will need: 3 Achieve finite course of treatment leading to functional cure rates >8-10%* 2 Ease of administration 1 A good safety & tolerabili
Slide 9: Inarigivir: A Novel, Oral, Selective Immunomodulator with a Dual Mechanism of Action
7 • SPRING BANK PHARMACEUTICALS, INC. © 2018 Potent RIG-I agonist INARIGIVIR: A NOVEL, ORAL, SELECTIVE IMMUNOMODULATOR WITH A DUAL MECHANISM OF ACTION Orally available, liver-selective immunomodulator Demonstrated dose response in HBV DNA and HBV RNA Favorable safety profile to date with no SAEs Dee
Slide 10: Inarigivir: Dual Mechanism of Action
8 • SPRING BANK PHARMACEUTICALS, INC. © 2018 INARIGIVIR: A NOVEL, ORAL SELECTIVE IMMUNOMODULATOR WITH A DUAL MECHANISM OF ACTION HBV, hepatitis B virus; IFN, interferon; pgRNA, pregenomic RNA; RIG-I, retinoic acid-inducible gene-I. Sato et al. Immunity. 2015;42:123-132. INARIGIVIR is a RIG–I AGONIST
Slide 11: Inarigivir MOA Studies Indicate Key Role for Selective Hepatic Immunomodulation
PRE-CLINICAL DATA Inarigivir binds to CARDs and regulatory domain of RIG-I with activation of IRF-3 and hepato-selective innate immune response Inarigivir up-regulates intra-hepatic RIG-I, activates intra-hepatic ISGs and suppresses HBsAg, HBV DNA, HBV RNA and cccDNA in the woodchuck CLINICAL Inarig
Slide 12: Clinical Studies of Inarigivir in HBV: ACHIEVE Phase II Dose Escalation Study
10 • SPRING BANK PHARMACEUTICALS, INC. © 2018 CLINICAL STUDIES OF INARIGIVIR IN HBV DNA, deoxyribonucleic acid; HBeAg, hepatitis B e antigen; RNA, ribonucleic acid; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; QD, once daily. PRIMARY ENDPOINT SECONDARY ENDPOINT Safety and antiviral ac
Slide 13: Global HBV Clinical Collaboration with Gilead
n=30 Vemlidy® monotherapy Inarigivir - 50 mg + Vemlidy® Inarigivir - 200 mg + Vemlidy® GLOBAL HBV CLINICAL COLLABORATION WITH GILEAD Inarigivir co-administered with Vemlidy® (tenofovir alafenamide) 25 mg in naïve patients Expanded Gilead Phase 2 HBV Study Vemlidy® 12 weeks 36 weeks Initiated by Gile
Slide 14: ACHIEVE Study Baseline Demographics Cohorts 1, 2, and 3
Placebo 25 mg HBeAg +ve 25 mg HBeAg -ve 50 mg HBeAg +ve 50 mg HBeAg -ve 100 mg HBeAg +ve 100 mg HBeAg -ve Number 11 9 7 11 5 13 4 Age 40 37 43 36 47 34 46 Gender M:F 7:4 5:5 3:3 9:2 5:0 7:6 3:1 Baseline ALT 69 82 75 75 65 75 90 Baseline HBV DNA log10 6.20 7.86 5.69 7.79 4.55 8.20 5.95 Genotype A 1 1
Slide 15: Positive Dose Response in HBeAg +ve Patients at Week 12
13 • SPRING BANK PHARMACEUTICALS, INC. © 2018 HBV DNA 1 0 -1 -2 Placebo 25 mg 50 mg 100 mg Placebo 25 mg 50 mg 100 mg HBV RNA 0.5 0.0 -1.0 -1.5 -0.5 -2.0 Inarigivir 100 mg vs PL *p<0.05 * # Inarigivir vs PL *p<0.03 #p<0.02 Inarigivir Inarigivir Log10 Decline HBV DNA Log10 Decline HBV RNA Inarigivir
Slide 16: Positive Dose Response in HBeAg -ve Patients at Week 12
14 • SPRING BANK PHARMACEUTICALS, INC. © 2018 INARIGIVIR DEMONSTRATES A CONTINUING POSITIVE DOSE RESPONSE IN HBeAg -VE PATIENTS AT WEEK 12 HBV DNA HBV RNA Placebo 25 mg 50 mg and 100 mg 4 2 -2 -4 0 -6 2 1 -1 -2 0 -3 Placebo 25 mg 50 mg 100 mg All groups p<0.01 All groups p<0.01 5 patients undetectab
Slide 17: Baseline HBsAg Predictor of Response of Both DNA and RNA to Inarigivir
Patients: HBsAg <4 log: 16 HBeAg –ve, 10 HBeAg +ve 15 • SPRING BANK PHARMACEUTICALS, INC. © 2018 IN ALL COHORTS: BASELINE HBsAg PREDICTOR OF RESPONSE OF BOTH DNA AND RNA TO INARIGIVIR 1 -1 -2 0 -3 Subjects with Baseline HBsAg >4 log Subjects with Baseline HBsAg <4 log HBV DNA p<0.001 Subjects with B
Slide 18: Effect of Oral Inarigivir on HBsAg
16 • SPRING BANK PHARMACEUTICALS, INC. © 2018 EFFECT OF ORAL INARIGIVIR (25, 50, AND 100 MG) ON HBsAg Only oral drug candidate to show meaningful effect on HBsAg in clinical studies Effect on HBsAg seen at all doses in both monotherapy and after TDF switch Overall, 13 of 47 (28%) patients experience
Slide 19: Effect of Oral Approved or Investigational HBV Drugs on HBsAg
17 • SPRING BANK PHARMACEUTICALS, INC. © 2018 EFFECT OF ORAL APPROVED OR INVESTIGATIONAL HBV DRUGS ON HBsAg* TLR-7 (Vesatolimod 4 mg) Week 12 mean reduction: 0.05 log10 No patient >0.5 log10 reduction No effect reported on HBsAg at week 4 TDF / TAF Week 48 mean reduction: HBeAg +ve 0.3 log10 HBeAg –
Slide 20: Inarigivir Development Plan Accounts for HBV Heterogeneity
70-80% of chronic HBV patients Dominant population in US & EU Older age group Lower viral burden SB 9225 + different MOA Inarigivir + existing oral anti-viral “Suppress & Shock” Inarigivir monotherapy “Stop & Shock” INARIGIVIR DEVELOPMENT PLAN ACCOUNTS FOR HBV HETEROGENEITY Naïve or new to treatment
Slide 21: Suppress & Shock: Adding Inarigivir in Virally Suppressed Patients
19 • SPRING BANK PHARMACEUTICALS, INC. © 2018 “SHOCK” inarigivir once daily for 12-24 weeks Durable HBsAg loss “SUPPRESS & SHOCK” ADDING INARIGIVIR IN VIRALLY SUPPRESSED PATIENTS Host immune system activated with the goal of clearing the virus Inarigivir immunomodulation anticipated to be studied in
Slide 22: Stop & Shock – Inarigivir Monotherapy
S 20 • SPRING BANK PHARMACEUTICALS, INC. © 2018 “SHOCK” inarigivir once daily for 12-24 weeks Virally suppressed patients stop NUC treatment 10-20% OF PATIENTS Host immune system detects and clears virus Experienced durable HBsAg loss up to 2 years after stopping treatment Inarigivir monotherapy ant
Slide 23: Stop & Shock – Inarigivir Monotherapy
“STOP & SHOCK” – INARIGIVIR MONOTHERAPY 21 • SPRING BANK PHARMACEUTICALS, INC. © 2018 “STOP & SHOCK” – INARIGIVIR MONOTHERAPY “Stop” approach is at the forefront of current innovative clinical HBV treatment + Adding inarigivir (“Shock”) to the “Stop” regimen, i.e., “Stop and Shock,” could enhance th
Slide 24: SB 9225 – Fixed-Dose Combination for Naïve HBV
SB 9225 (inarigivir + TDF) Ph IIb / III program in US, EU and ASIA (anticipated Q3 2019) Newly diagnosed chronic HBV patients SB 9225 once-daily vs. TDF alone 24 week duration of treatment Primary endpoints: HBV DNA & durable HBsAg loss SB 9225 + other MOA (i.e., siRNA, capsid) – addressing HBsAg hi
Slide 25: Inarigivir and SB 9225 Leading the Way as Backbone for HBV Development – Planned Clinical Studies
INARIGIVIR and SB 9225 LEADING THE WAY AS BACKBONE FOR HBV DEVELOPMENT – PLANNED CLINICAL STUDIES 23 • SPRING BANK PHARMACEUTICALS, INC. © 2018 Q1 Q2 Q3 Q1 Q2 Q3 Q4 2018 Q4 2019 Ph 2 ACHIEVE 200 mg monotherapy arm “Stop & Shock” inarigivir monotherapy Ph 2b/3 in low viral burden patients “Suppress &
Slide 26: SB 11285 A Novel Synthetic STING Agonist Lead Compound
SB 11285 A NOVEL SYNTHETIC STING AGONIST LEAD COMPOUND A NOVEL SYNTHETIC
Slide 27: STING Agonist – Potent Activator of Innate Immune Response
ATP cGAS 5’ 2’ 3’ 6’ GTP STING AGONIST – POTENT ACTIVATOR OF INNATE IMMUNE RESPONSE Potential component of I/O strategies to turn cold tumors “hot” IV administration could be next frontier of STING agonist development Activation of Type I IFN could enhance efficacy in combination with checkpoint inh
Slide 28: SB 11285 – Lead Next Generation STING Agonist
26 • SPRING BANK PHARMACEUTICALS, INC. © 2018 SB 11285 – Lead next generation STING agonist Shown to be highly potent & efficacious across multiple preclinical cancer models with associated abscopal and tumor memory responses Potentially first IV STING agonist to enter clinic Differentiated cyclic d
Slide 29: SB 11285 Significantly Inhibited Tumor Growth in Relevant Oncology Models
27 • SPRING BANK PHARMACEUTICALS, INC. © 2018 SB 11285 SIGNIFICANTLY INHIBITED TUMOR GROWTH IN RELEVANT ONCOLOGY MODELS Efficacy in relevant oncology animal models observed with intravenous (IV), intraperitoneal (IP) and intratumoral (IT) delivery 1600 1400 1200 1000 800 600 400 200 0 1 5 9 12 Days
Slide 30: The Path Forward for Spring Bank: Potential for Multiple Catalysts
28 • SPRING BANK PHARMACEUTICALS, INC. © 2018 2018 2019 THE PATH FORWARD FOR SPRING BANK POTENTIAL FOR MULTIPLE CATALYSTS 1. As of September 30, 2018. CMC, chemistry, manufacturing and controls; IND, Investigational new drug. 2H 2018 Complete monotherapy dosing in the 200 mg cohort of the ACHIEVE Ph
Slide 31: A Focus on Simplicity, Safety, and Selectivity
29 • SPRING BANK PHARMACEUTICALS, INC. © 2018 SPRING BANK PHARMACEUTICALS, INC. A FOCUS ON SIMPLICITY, SAFETY, AND SELECTIVITY SB 9225 (inarigivir + TDF) Simplifies combination therapy Next-generation STING agonist program: Lead SB 11285 anticipated to enter clinic in multiple cancers in 2019 Antici
Spring Bank Pharmaceuticals — Investor Presentation (November 2018) on 6ix